A Phase I/II Trial of ABI-008 (Nab-Docetaxel) in Patients With Hormone-Refractory Prostate Cancer.

Trial Profile

A Phase I/II Trial of ABI-008 (Nab-Docetaxel) in Patients With Hormone-Refractory Prostate Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 10 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jun 2011 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.
    • 09 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top